About DocDoz Pharma
DocDoz Pharma is a company based in Hubli (India) founded in 2022. The company has 12 employees. DocDoz Pharma offers products and services including MoxiDoz CV-625 Tablets and DocCef 200 DT Tablets.
- Headquarter Hubli, India
- Employees 12
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Legal Name Docdoz Pharma Pvt. Ltd
- Date of Incorporation 04 Jan, 2022
- Jurisdiction Hubli, Karnataka, India
- Annual Revenue₹53 Lakh
FY 2023
- Net Loss-₹16.3 Lakh
FY 2023 · -31% margin
- EBITDA-₹22.4 Lakh
FY 2023 · -42% margin
- Employee Count12
Associated legal entities of DocDoz Pharma
DocDoz Pharma operates through Docdoz Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Docdoz Pharma Private Limited CIN U24230KA2022PTC156228 | Active | 04 Jan 2022 | Hubli, Karnataka | ₹0.5 Cr | 12 | 4 | View details |
Products & Services of DocDoz Pharma
DocDoz Pharma offers a comprehensive portfolio of products and services, including MoxiDoz CV-625 Tablets and DocCef 200 DT Tablets.
These tablets are utilized for treating bacterial infections and are supplied through distribution channels to ensure availability.
These tablets are employed for antibiotic purposes and are made available across the country via established networks.
Board of directors of Docdoz Pharma Private Limited (DocDoz Pharma)
Docdoz Pharma Private Limited is the primary company behind DocDoz Pharma. The board of Docdoz Pharma Private Limited currently have 4 directors; the longest-serving is Sanjeev Parashuram Naik, appointed in 2022. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjeev Parashuram Naik DIN 09456224 | Director | 04 Jan 2022 | 4 yrs 9 mo | Docdoz Pharma Private Limited |
| Varun Patel DIN 09456225 | Director | 04 Jan 2022 | 4 yrs 9 mo | Docdoz Pharma Private Limited |
| Sunil Pattar DIN 09504593 | Director | 18 Feb 2022 | 4 yrs 7 mo | Docdoz Pharma Private Limited |
| Mruthyunjaya Mimgaya Bhandarinath DIN 09510476 | Director | 18 Feb 2022 | 4 yrs 7 mo | Docdoz Pharma Private Limited |
Financials of DocDoz Pharma
Figures of Docdoz Pharma Private Limited, the primary company behind DocDoz Pharma, for FY 2023. Revenue was ₹53 Lakh. Net loss was -₹16.3 Lakh (-31% margin). EBITDA was -₹22.4 Lakh (-42% margin).
- ₹53 LakhRevenue · FY 2023
- -₹16.3 LakhNet loss · -31% margin
- -₹22.4 LakhEBITDA · -42% margin
- ₹15 LakhPaid-up capital
- 12Employees (provident fund records)
Balance sheet, profit and loss, cash flow and ratios of Docdoz Pharma Private Limited are on its company page.
Detailed financial statements for DocDoz Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to DocDoz Pharma
10 companies that operate in the same segment as DocDoz Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DocDoz Pharma
DocDoz Pharma was founded in 2022.
DocDoz Pharma is headquartered in Hubli, India. It is registered at Hubli, Karnataka, India.
DocDoz Pharma has 12 employees.
The primary company behind DocDoz Pharma, Docdoz Pharma Private Limited, reported revenue of ₹53 Lakh for FY 2023.
DocDoz Pharma Pvt. Ltd. was established on January 4, 2022, with the objective of making affordable medicines accessible to the financially disadvantaged in society. Products are manufactured in WHO GMP Certified facilities, adhering to global standards for quality, efficiency, and packaging. A well-structured distribution network is utilized to ensure availability across various states in India. The companys vision is directed towards reaching every corner of the country by 2032, while its mission emphasizes providing chronic disease treatments at prices that cater to the needs of the most vulnerable populations.
DocDoz Pharma offers MoxiDoz CV-625 Tablets and DocCef 200 DT Tablets.
DocDoz Pharma operates through Docdoz Pharma Private Limited.
The legal entities of DocDoz Pharma currently have 4 directors, including Sunil Pattar, Mruthyunjaya Mimgaya Bhandarinath, Sanjeev Parashuram Naik and others.